Carcinoma of Unknown Primary – an Orphan Disease? by Krämer, Alwin et al.
Review Article · Übersichtsarbeit
Breast Care 2008;3:164–170 Published online: June 19, 2008
DOI: 10.1159/000136001
Schlüsselwörter
CUP-Syndrom · Metastasen bei unbekanntem 
Primärtumor · Metastasen · Cetuximab 
Zusammenfassung
Unter dem Cancer of Unknown Primary (CUP)-Syndrom
werden diejenigen Tumorerkrankungen zusammenge-
fasst, bei denen auch nach Abschluss der Diagnostik
nur Metastasen, jedoch kein Primärtumor gefunden
wird. Das CUP-Syndrom macht ca. 3–5% aller neu dia-
gnostizierten Malignomfälle aus und umfasst eine
heterogene Gruppe von Tumoren, die die Fähigkeit zur
Metastasierung erlangt haben bevor sich ein klinisch
manifester Primärtumor entwickelt hat. Obwohl bemer-
kenswerte Fortschritte in der Behandlung von Patienten
mit bestimmten, gut definierten Erkrankungssubgrup-
pen, wie beispielsweise Frauen mit isolierter Peritoneal-
karzinose oder jungen Erwachsenen mit gering differen-
zierten Karzinomen mit Mittellinienverteilung, erzielt
werden konnten, ist die Prognose bei der Mehrzahl der
Patienten nach wie vor schlecht. Wir berichten im wei-
teren Verlauf dieser Übersichtsarbeit über Fortschritte
in der Diagnostik und Therapie von Patienten mit CUP-
Syndrom und weisen darauf hin, dass es trotz der
immer noch sehr schlechten Prognose von großer
 Bedeutung ist, Patienten mit bestimmten Subtypen des
CUP-Syndroms zu identifizieren, die spezifischen The-
rapien mit der Option auf Heilung zugeführt werden
sollten. Darüber hinaus möchten wir auf neuere dia-
gnostische und therapeutische Bestrebungen aufmerk-
sam machen, die das Verständnis und die Prognose
dieses auch in der Onkologie bisher stiefmütterlich
 behandelten Krankheitsbildes hoffentlich verbessern
werden.
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Summary
Carcinoma of unknown primary (CUP) is an intriguing
clinical finding that is defined as biopsy-proven metas-
tasis from a malignancy in the absence of an identifi-
able primary site after a complete clinical work-up. CUP
is a relatively common clinical entity, accounting for ap-
proximately 3–5% of all cancer diagnoses, and consists
of a heterogeneous group of tumors that have acquired
the capacity to metastasize before the development of a
clinically evident primary lesion. Notable advances
have been made over the past years in the treatment of
well-defined clinical subgroups of CUP, such as women
with peritoneal carcinomatosis and young adults with
poorly differentiated carcinomas of midline distribution,
but for the majority of patients, the prognosis still re-
mains poor. In this review, we highlight recent advances
in the diagnosis and treatment of patients with CUP
syndrome, and emphasize the importance of identify-
ing several favorable subsets of CUP, amenable to spe-
cific treatment options. In addition, we will point out
novel diagnostic and therapeutic approaches which will
hopefully improve both our understanding and the
prognosis of this more or less neglected disease.
Prof. Dr. med. Alwin Krämer
Klinische Kooperationseinheit für Molekulare Hämatologie und Onkologie des 
DKFZ und der Medizinischen Klinik und Poliklinik V der  Universität Heidelberg 
Im Neuenheimer Feld 581, 69120 Heidelberg, Germany
Tel. +49 6221 42144-0, Fax -4
E-mail Alwin_Kraemer@med.uni-heidelberg.de
Carcinoma of Unknown Primary – an Orphan Disease?
Alwin Krämera Gerdt Hübnerb Andreas Schneeweissc Gunnar Folprechtd Kai Nebene
a Klinische Kooperationseinheit für Molekulare Hämatologie und Onkologie des Deutsches Krebsforschungszentrums und der
 Medizinischen Klinik und Poliklinik V der Universität Heidelberg,
bSana Kliniken Ostholstein, Oldenburg,
c Frauenklinik, Universität Heidelberg,
dMedizinische Klinik I, Universität Dresden,
e Medizinische Klinik und Poliklinik V, Universität Heidelberg, Germany
© 2008 S. Karger GmbH, Freiburg
Accessible online at: 
www.karger.com/brc
Fax +49 761 4 52 07 14
E-mail Information@Karger.de
www.karger.com
BreastCare
164_170_03003_kraemer:164_170_03003_kraemer  25.06.2008  7:56 Uhr  Seite 164
Introduction
Carcinoma of unknown primary (CUP) is defined as biopsy-
proven metastasis from a malignancy in the absence of an
identifiable primary site after a complete history and physi-
cal examination, basic laboratory studies, computed tomogra-
phy (CT) scans, and additional directed studies indicated by
positive findings during the initial work-up [1]. CUP repre-
sents 3–5% of all cancers among males and females, and is
slightly more common in men. The median age at diagnosis is
65–70 years. CUP is extremely rare in children. Survival is
poor. Empiric chemotherapy with newer, primarily tax-
ane/platinum- or gemcitabine/platinum-based regimens have
produced response rates between 30–40%, with 1- and 2-year
survivals of approximately 50 and 25%, respectively [2–5].
Complete remissions with these regimens are rare, and the
remission duration is usually brief.
A careful and comprehensive pathological examination of
biopsied metastatic lesions is crucial for the diagnosis of CUP.
Histologically, these tumors can be divided into the following
pathological groups [6–9]: i) adenocarcinoma (50–70%); ii) un-
differentiated carcinoma (20–30%); iii) squamous cell carcino-
ma (5–8%); iv) undifferentiated tumors (2–3%). Neuroen-
docrine carcinoma (2–4%) is often mentioned separately be-
cause this entity belongs to a treatable subset [10]. Although
CUP is a heterogeneous group of tumors with widely diverse
natural histories, clinically, they exhibit common typical charac-
teristics: Usually patients present with a short history of non-
specific complaints [11]. The primary tumor remains unidenti-
fied throughout life in most cases. Before death, the primary
tumor is identified in only 10–20% of cases despite an exten-
sive radiographic and endoscopic search [1, 12, 13]. In contrast
to patients with metastasized known primaries, in whom the
percentage of cases with 3 or more organs involved is below
15% at diagnosis, this number equals approximately 30% in
patients with CUP [14, 15]. Lastly, an unusual pattern of distant
spread has been reported in large autopsy studies [8, 13, 16].
These findings argue in favor of the hypothesis that CUP
comprises a distinct biological disease entity. Nevertheless,
there is a long-lasting and still ongoing debate as to whether
or not CUP simply reflects metastases shed by a well hidden
primary. After evaluation at autopsy, 55–85% of the pri-
maries are found in patients with CUP. Usually, they are
small tumors, most often located in the pancreas (20–26%)
and lung (17–23%), followed by sites in the colon or rectum
(4–10%), liver (3–11%), stomach (3–8%), kidney (4–6%),
ovary (3–4%), prostate (3–4%), or breast (2%) [1, 8] (fig. 1).
Diagnostic Evaluation in Carcinomas of Unknown
 Primary
When metastatic disease is documented in the absence of a
primary site, a careful selection of diagnostic tests is of para-
mount importance to maximize the chances of identifying
the primary tumor and additional metastatic sites on the one
hand, but to minimize treatment delay, patient risk, and in-
convenience and costs associated with a lengthy work-up on
the other hand. The basic diagnostic strategy in patients with
metastases in the absence of an obvious primary tumor com-
prises a detailed patient history and physical examination,
gynecological examination in women, basic laboratory stud-
ies, CT scans of the neck, chest, abdomen, and pelvis, and –
most importantly – a tumor biopsy. Several recent reviews
cover immunohistological strategies applied in order to iden-
tify occult primary tumors in CUP patients [17, 18]. In addi-
tion to basic laboratory parameters, the analysis of only a few
tumor markers has been proven to have an impact on future
therapeutic strategies. Among those are AFP (hepatocellular
carcinoma), β-hCG (germ cell tumors), PSA (prostate can-
cer), and calcitonin (medullary thyroid carcinoma). Other
markers including CEA, Ca125, Ca19–9, and Ca15–3 lack
specificity and may serve as follow-up parameters at the
most. The role of endoscopy, established in the evaluation of
patients with squamous cell carcinoma involving cervical
lymph nodes [19], remains incompletely defined in CUP
 patients not belonging to this favorable clinicopathological
subset, and currently appears justified only in patients 
with clinicopathological characteristics suggesting a primary
 gastrointestinal or lung carcinoma.
Positron emission tomography with fluorodesoxyglucose
(FDG-PET) can be used for the detection of both occult pri-
mary tumors and additional metastatic sites in patients with
CUP syndrome. With the exception of cervical metastases of
unknown primary, PET has only been little explored for
CUP patients. However, a recent meta-analysis on 221 pa-
tients from 10 studies suggests that in 41% of patients, a
 primary tumor site could be identified after conventional
 diagnostics had failed to do so, although the extent of con-
ventional diagnostics employed was heterogenuous in these
studies [20]. In 59% of the cases, the primary tumor was
found in the lungs. Moreover, in 37% of the patients, addi-
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Pancreas 20-26%
Lung 17-23%
Liver 3-11%
Colon/Rectum 4-10%
Kidney 4-6%
Breast 2%
Fig. 1. Primary tumor sites in patients with CUP. The displayed frequen-
cies are derived from historical autopsy studies [1, 8].
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tional metastatic sites were identified. PET significantly
changed the clinical management in approximately one third
of the patients studied but had a notably high false-positive
rate (58%) for tumors of the lower digestive tract. In patients
with cervical metastases of unknown primary, the diagnostic
value has been more extensively explored. Here, several
studies suggest that a primary tumor site can be identified in
one third of patients, and the therapeutic strategy is modi-
fied in approximately on third of cases as well [21, 22]. These
preliminary data suggest that PET may have a role in the
identification of both occult primary tumors and additional
metastases in CUP patients, but additional studies are neces-
sary to further specify its role in this disease entity.
The Importance of Identifying CUP Subsets
From several studies, it became evident that some patients
responded better to specific therapies than others, and treat-
able subgroups with a better prognosis due to specific treat-
ment were recognized: i) squamous cell carcinoma involving
the upper or mid-cervical lymph nodes; ii) squamous cell car-
cinoma involving the inguinal lymph nodes; iii) women with
axillary lymph node metastases; iv) women with peritoneal
carcinomatosis; v) men with bone metastases and/or elevated
PSA; vi) men with features of extragonadal germ cell tumors;
vii) poorly differentiated neuroendocrine tumors; viii) CUP
in a single site. Although patients who fit into one of these
subsets comprise only a minority of CUP cases, early re -
cognition of these patients is important, because specific
treatments can improve outcome, and increase survival.
Since several excellent overviews on this topic have been
published [23], we here will specifically emphasize only those
subgroups with suspected underlying gynecological malig-
nancies.
Squamous Cell Carcinoma Involving the Inguinal Lymph
Nodes
CUP involving the inguinal lymph nodes is rare and accounts
for only 1–3.5% of all CUP cases [11, 24]. In most patients
with inguinal metastases of a squamous cell carcinoma, a pri-
mary tumor can be detected in the genital or anorectal area.
Identification of a primary site seems especially important in
these patients, since carcinomas of the cervix, vagina, vulva,
and anus are amenable to curative treatment options even
after they have spread to the regional lymph nodes. If no pri-
mary site can be identified, inguinal lymph node dissection
and/or radiation treatment can result in long-term survival
[24]. However, due to the rarity of squamous cell carcinoma
of unknown primary involving the inguinal lymph nodes, sys-
tematic studies of combined modality therapy have not been
published. In a review of 56 cases, local excision alone led to
a 5-year survival rate of 33% [24]. After irradiation alone, a
similar 5-year survival rate of 35% has been reported [24].
These findings suggest that radiation therapy is a valid alter-
native to surgery in the management of these cases. Based
on the patterns of failure following radiation therapy and the
fact the primary tumors do only very rarely manifest them-
selves subsequently in these cases, treating more than the
local area of involvement cannot be advocated.
Women with Axillary Lymph Node Metastases
Metastatic adenocarcinoma involving the axillary lymph
nodes in women is highly suggestive for metastatic breast
cancer, especially when the cells express HER2 and/or sex
hormone receptors [25]. However, hormonal receptors (es-
trogen and progesterone) are negative in 70–80% of cases. In
these women, the initial work-up should include mammogra-
phy, breast ultrasound, magnetic resonance imaging (MRI)
of the breasts, and PET scanning [26, 27]. MRI of the breast
enables the identification of an occult breast primary tumor
in about 75% of women who present with adenocarcinoma
in the axillary lymph nodes. The value of PET scanning is
more controversial. FDG-PET identified the primary tumor
in only about 25% of these cases [28]. At diagnosis, only 5%
of these patients present with distant metastases [29]. The
clinical characteristics of patients with CUP associated with
axillary metastasis appear to be comparable to patients with
stage II breast cancer. Reports by several groups suggest that
the survival rates of patients with T0 N1 breast cancer may
even be higher than those of patients with non-occult stage II
breast tumors [30, 31].
With regard to treatment, breast surgery and breast irradia-
tion are not recommended if MRI fails to identify a primary
breast tumor. Based on data by Vlastos et al. [32], it has been
shown that no difference was detected in the rates of locore-
gional recurrence and distant metastases or 5-year survival
between mastectomy and breast preservation in women with
occult primary carcinoma presenting with axillary lymph
node metastasis. Axillary lymph node dissection is important
for histopathological diagnosis, locoregional control, and
prognostic information. Analogous to non-occult breast can-
cer, the most important determinant of survival in CUP with
axillary lymph node involvement is the number of positive
nodes: 5-year overall survival was 87% in patients with 1–3
positive nodes, compared to 42% in women with 4 or more
positive lymph nodes [32]. In patients with occult primary
breast cancer who have undergone axillary lymph node dis-
section and observation of the breast, breast cancer devel-
oped in subsequent years in 14–53% [31, 33]. In contrast, in
women who have received axillary lymph node dissection
with subsequent breast irradiation, the incidence of breast
cancer development ranged from 12 to 33% [33–35]. Also,
the addition of radiotherapy has been shown to have a signif-
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icant impact on survival in this situation with 91 vs. 43% sur-
viving with and without radiotherapy, respectively [32]. Thus,
breast preservation with radiation treatment might be appro-
priate in these cases. However, these series of patients have
been reported before breast MRI was used on a routine
basis. Therefore, it remains unclear whether these results
apply to patients with a normal breast MRI. Adjuvant
chemotherapy and endocrine therapy protocols should fol-
low the guidelines for stage II breast cancer. In patients with
N2 disease, neoadjuvant chemotherapy in analogy to breast
cancer treatment is recommended.
Women with Peritoneal Carcinomatosis
Adenocarcinoma causing diffuse peritoneal involvement in
women, usually originates in the ovary, although primaries in
breast or gastrointestinal tract may occasionally produce this
syndrome. Histological features like papillary configuration
or psammoma bodies are suggestive for ovarian carcinoma.
In these cases, the syndrome has been termed ‘multifocal ex-
traovarian serous carcinoma’ or ‘peritoneal papillary serous
carcinoma’. However, some patients have poorly differentiat-
ed carcinoma, resembling poorly differentiated epithelial
ovarian carcinoma. These patients should be treated accord-
ing to the guidelines for stage III ovarian cancer, including
initial maximal surgical cytoreduction, followed by a tax-
ane/platinum-based chemotherapy [36].
Carcinoma of Unknown Primary in a Single Site
Approximately one third of the patients presenting with CUP
have a unique metastatic site. The most frequent locations are
liver, bones, lungs, and lymph nodes [37, 38]. Median survival is
20 months in patients with localized CUP as compared to 7
months in cases that presented with disseminated disease [39].
In addition to standard diagnostic procedures, a PET scan
might be specifically helpful in this patient group, primarily to
exclude additional metastatic sites [40]. In most patients pre-
senting with a single metastatic lesion, other metastatic sites be-
come apparent within a relatively short time. However, defini-
tive local treatment sometimes produces prolonged disease-
free intervals. Moreover, occasionally, patients have prolonged
survival. Therefore, resection of the solitary lesion should be
undertaken if feasible. In addition, postoperative irradiation
seems appropriate to maximize the likelihood of local control
[41, 42]. With regard to additional adjuvant chemotherapy, sys-
tematic studies proving its superiority as compared to local
treatment alone are lacking. Accordingly, such a strategy can-
not be recommended until more data support this concept.
Treatment of Patients with Carcinoma of Unknown
 Primary
Although several clinicopathologic subsets with a favorable
prognosis have been identified, most patients do not fit into
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Table 1. Prospective randomized trials in patients with CUP
Study [reference] Patients, Chemotherapy regimen Response rate, % Median PFS, Median OS, 
n months months
Palmeri et al., 2006 [53] 66 cisplatin + gemcitabine + paclitaxel 48.5 vs. 42.3 NA 9.6 vs. 13.6
vs. cisplatin + gemcitabine + vinorelbine
Huebner et al., 2005 [60] 92 carboplatin + paclitaxel vs. 23.8 vs. 20.0 7.0 vs. 3.2 11.0 vs. 6.1
gemcitabine + vinorebine 
Culine et al., 2003 [54] 80 cisplatin + gemcitabine vs. cisplatin 55 vs. 38 5 vs. 4 8 vs. 6
+ irinotecan 
Assersohn et al., 2003 [55] 88 5-FU vs. 5-FU + mitomycin-C 11.6 vs. 20 (NS) 4.1 vs. 3.6 (NS) 6.6 vs. 4.7 (NS)
Dowell et al., 2001 [56] 34 carboplatin + etoposid vs. paclitaxel 19 vs. 19 (NS) NA 6.5 vs. 8.4 (NS)
+ 5-FU + folic acid 
Falkson et al., 1998 [57] 84 cisplatin + epirubicin + mitomycin-C 50 vs. 17 4.5 vs. 2.0 9.4 vs. 5.4 
vs. mitomycin-C (p = 0.05) (p = 0.05) 
Eagan et al., 1987 [2] 55 cisplatin + doxorubicin + mitomycin-C 27 vs. 14 (NS) NA 4.6 vs. 5.5 (NS)
vs. doxorubicin + mitomycin-C 
Milliken et al., 1987 [58] 101 cisplatin + vinblastin + bleomycin 32 vs. 42 NA 6.2 vs. 4.5 (NS)
vs. doxorubicin + mitomycin-C 
Woods et al., 1980 [59] 47 cyclophosphamide + methotrexate 5 vs. 36 (p < 0.01) NA 1.7 vs. 4.5 (NS)
+ 5-FU vs. doxorubicin + mitomycin-C 
CUP = Carcinoma of unknown primary; 5-FU = 5-flurouracil; NA = not available; NS = not statistically significant; PFS = progression-free survival;
OS = overall survival.
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any of these subgroups. About 50–70% of CUP patients suf-
fer from disseminated adeno- or undifferentiated carcinoma,
where local treatment strategies are not an option. Five
prospective phase II trials by the Minnie Pearl Cancer
 Research Network analyzing different platinum/taxane
 combinations established a total response rate of 30%, with
94% partial responders and 6% complete responders, a
 median survival of 9.1 months, 1- and 5-year survivals of 38
and 8%, and 1- and 5-year progression-free survivals of 17
and 4%, respectively [5, 43–46]. Importantly, no difference in
survival with any of the combinations used, or between
 poorly differentiated and adenocarcinomas, was found.
Randomized prospective trials proving that any form of
chemotherapy improves the survival of CUP patients with
disseminated adeno- or undifferentiated carcinoma over
best supportive care alone are lacking. Nevertheless, com-
parison with historical data from large patient collections 
[6, 7, 9, 47–52] which show 1- and 5-year survival rates of 20
and 5%, respectively, demonstrates that newer taxane/
platinum-based chemotherapy regimens have led to a signi -
ficant improvement of survival. Only very few randomized
clinical trials comparing different chemotherapy regimens to
each other have been reported for CUP patients at all [2,
53–60]. These are summarized in table 1 and basically sup-
port the view that platinum-based regimens are superior to
combinations without platinum. Therefore, the standard
chemotherapy for good performance status CUP patients
with disseminated adeno- or undifferentiated carcinoma
nowadays consists of a taxane/platinum combination. Be-
cause of the lower toxicity of carboplatin as compared to cis-
platin, the favored regimen is carboplatin/paclitaxel. With
this combination, response rates of 30–40% and a 2-year
survival rate of 20–25% can be achieved if administered as
first-line therapy.
Only a few second-line chemotherapy regimens for patients
with CUP have been evaluated, and these have produced low
response rates. During recent years, single agent gemcitabine
and the combination of gemcitabine with irinotecan has been
evaluated as a second-line treatment in patients with CUP
[61, 62]. Although both treatments had modest activity, re-
sponse rates of only 8 and 10% were achieved, and median
survival was short (3 and 4.5 months, respectively). Taken
 together, although CUP patients with disseminated adeno-
or undifferentiated carcinoma certainly attain clinical benefit
and prolonged survival from modern chemotherapy regi-
mens, there is an urgent need for improvement, both in 
first- and second-line treatment strategies.
Analogous to several other tumor entities, progress in the
treatment of patients with CUP might come from the use of
agents with novel mechanisms of action. Although data on
CUP biology including mutation status and expression levels
of oncogenes and tumor suppressors are scarce, it has recent-
ly been reported that, in contrast to HER2 and c-Kit which
were detected in only 4 and 10% of CUP patients, respec-
tively, the epidermal growth factor receptor (EGFR) is ex-
pressed in 66% of CUP tumors [63]. Of note, EGFR expres-
sion was correlated to tumor chemosensitivity towards plat-
inum-based chemotherapy in this study. Also, recent data
show that in a group of predominantly pretreated patients
with mostly disseminated adeno- or undifferentiated car -
cinoma, a combination of erlotinib and bevacizumab 
which target EGFR and vascular endothelial growth factor
(VEGF), respectively, leads to a median survival of 7.4
months and a 1-year survival rate of 33% [64], which appears
substantially improved when compared retrospectively with
other second-line regimens and, in fact, is similar to the
 survival reported for many first-line chemotherapies.
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Patients with newly diagnosed disseminated CUP
Histology: undifferentiated or adenocarcinoma
Study Design
Randomized Phase III Study
Randomization
6 x Carboplatin + Paclitaxel 6 x Carboplatin + Paclitaxel
+ Cetuximab
n=75 n=75
Fig. 2. Concept of a prospective, randomized trial comparing the current
treatment standard carboplatin/paclitaxel with carboplatin/paclitaxel plus
cetuximab in patients with newly diagnosed adeno- or undifferentiated
CUP syndrome.
Fig. 3. Outline of the gene expression analysis procedure using tumor
biopsy samples from patients treated in the prospective randomized trial
as depicted in figure 2. The expression profiles of the analyzed samples
will be compared with gene expression profiles from tumors with known
primary sites.
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Derived from these data, the CUP working group of the
 German Cancer Society has decided to add the anti-EGFR
antibody cetuximab which has been shown to be effective in
colorectal, head and neck, and non-small cell lung cancer
[65–68] to the current standard chemotherapy regimen car-
boplatin/paclitaxel, and to compare its efficacy with carbo-
platin/paclitaxel chemotherapy alone in a prospective, ran-
domized trial (fig. 2). In addition, this study will include
 molecular profiling analyses at both the genomic and the ex-
pression level (fig. 3). This will hopefully result in a deepened
understanding of the biology and the identification of novel
molecular targets for the treatment of this up to now more or
less neglected disease.
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